Researchers will soon undertake one of the largest-ever long-term clinical trials of a system designed to help regulate blood sugar levels of individuals with type 1 diabetes mellitus. If the so-called artificial pancreas system performs in patients as hoped, it could lead to commercial trials and eventual regulatory approval in the United States and abroad.
A new study reveals the substantial impact of skipping breakfast on type-2 diabetics. 'Fasting' until noon triggers major blood sugar spikes (postprandial hyperglycemia) and impairs the insulin responses of type-2 diabetics throughout the rest of the day, researchers say.
Researchers at the Toronto General Hospital Research Institute have discovered metformin (the most widely prescribed type 2 diabetic medication) and resveratrol, a compound found in grapes, peanuts and blueberries, trigger novel signaling pathways in the small intestine to lower blood sugar.